Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884961 | 1.00 | L3MBTL1 (0.52) | L3MBTL1GAAMAPTALDH1A1MEN1 | |
| SCHEMBL8344229 | 1.00 | L3MBTL1 (0.52) | L3MBTL1GAAMAPTALDH1A1MEN1 | |
| SCHEMBL21651099 | 0.90 | SMN1; SMN2 (0.43) | L3MBTL1GAAMAPTALDH1A1MEN1 | |
| SCHEMBL28825701 | 0.83 | L3MBTL1 (0.59) | L3MBTL1GAAMAPTALDH1A1MEN1 | |
| SCHEMBL21090669 | 0.81 | L3MBTL1 (0.54) | L3MBTL1GAAMAPTALDH1A1MEN1 | |
| SCHEMBL5204300 | 0.78 | HSD17B10 (0.54) | MAPTALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL5204312 | 0.78 | HSD17B10 (0.54) | MAPTALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL8342694 | 0.78 | HSD17B10 (0.54) | MAPTALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL18665944 | 0.78 | TP53 (0.56) | L3MBTL1GAAMAPTALDH1A1MEN1 | |
| SCHEMBL5207675 | 0.78 | TP53 (0.60) | L3MBTL1GAAMAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350173-B1 | STEREOSELECTIVE PROCESS | BOEHRINGER INGELHEIM INT (DE) | 2020-02-12 | — | — | EP | disclosed |
| EP-3599234-A1 | STEREOSELECTIVE PROCESS | Boehringer Ingelheim International GmbH (DE) | 2020-01-29 | — | — | EP | disclosed |
| US-10189776-B2 | Stereoselective process | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-29 | — | — | US | disclosed |
| US-20180258031-A1 | STEREOSELECTIVE PROCESS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-09-13 | — | — | US | disclosed |
| EP-3350173-A1 | STEREOSELECTIVE PROCESS | Boehringer Ingelheim International GmbH (DE) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017046355-A1 | STEREOSELECTIVE PROCESS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| US-7691854-B2 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-06 | — | — | US | disclosed |
| EP-1537081-B1 | DIHYDROPYRIDINE DERIVATIVES FOR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-10-15 | — | — | EP | disclosed |
| EP-1554246-B1 | DIHYDROPYRIDINONE DERIVATIVES AS HNE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2007-08-22 | — | — | EP | disclosed |
| US-20070167406-A1 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-19 | — | — | US | disclosed |
| US-7230017-B2 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20060100207-A1 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2006-05-11 | — | — | US | disclosed |
| EP-1554246-A2 | DIHYDROPYRIDINONE DERIVATIVES AS HNE INHIBITORS | Bayer HealthCare AG (DE) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004020410-A2 | DIHYDROPYRIDINONE DERIVATIVES AS HNE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100207-A1 | Dihydropyridinone derivatives | TNNI3, DHPS, TNNT2 | L3MBTL1 4385/4885GAA 2947/4885MAPT 4727/4885 |
| US-10189776-B2 | Stereoselective process | CYP4A11, CYP4B1, CYP3A4 | L3MBTL1 4885/4885GAA 669/4885MAPT 3256/4885 |
| US-20180258031-A1 | STEREOSELECTIVE PROCESS | CYP4A11, CYP4B1, CYP3A4 | L3MBTL1 4885/4885GAA 669/4885MAPT 3256/4885 |
| US-20070167406-A1 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | SERPINB1, ELANE, MPO | L3MBTL1 4487/4885GAA 394/4885MAPT 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.